Over‐expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas
- 15 January 2021
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 30 (5) , 698-704
Abstract
Periostin, an extracellular matrix macromolecule implicated in tumorigenesis, serves as a prognostic marker for many cancer types. However, there are no data on periostin expression in cutaneous squamous cell carcinoma (cSCC). This study examined periostin expression in patients with cSCC and explored its clincopathological relationship and prognosis. Using immunohistochemistry and ImageJ analysis, we compared periostin expression in 95 cSCCs across a spectrum of cSCC aggressiveness: cSCC in situ (SCCIS) (n = 25), low‐risk cSCC (LR‐cSCC) (n = 26), high‐risk cSCC (HR‐cSCC) (n = 38), and cSCC in recessive dystrophic epidermolysis bullosa patients (RDEB cSCC) (n = 6). Immunohistochemistry demonstrated periostin expression within the intra‐tumoral stroma but not within tumor cells. Periostin levels significantly (P < 0.001) increased from SCCIS, LR‐cSCC, HR‐cSCC to RDEB SCC. The stroma of most of the cSCCs we evaluated contained cancer‐associated fibroblasts with a myofibroblastic (α ‐SMA‐positive) phenotype. Co‐localization of periostin with α‐SMA, evidence of fibroblast periostin expression, and absence of keratinocyte or tumor cell periostin expression suggest that, in cSCC, periostin is a product of the peritumoral microenvironment and not the tumor cells themselves. Our data indicate that fibroblast periostin expression is highly correlated with the aggressiveness of cSCC, and may thereby provide a molecular marker that will be useful for subtyping and diagnosing cSCCs according to their biological nature.Keywords
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH‐1810558)
- National Institutes of Health (AR33625, RC4AR060535)
This publication has 17 references indexed in Scilit:
- APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosaScience Translational Medicine, 2018
- Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma developmentMatrix Biology, 2017
- Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinomaviacreating a cancer-supportive nicheOncotarget, 2015
- Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer CellsCellular Physiology and Biochemistry, 2015
- Overexpression of Periostin in Stroma Positively Associated with Aggressive Prostate CancerPLOS ONE, 2015
- Tumour–stroma crosstalk in the development of squamous cell carcinomaThe International Journal of Biochemistry & Cell Biology, 2014
- Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis BullosaCancer Research, 2012
- Non-melanoma skin cancerThe Lancet, 2010
- The multifaceted role of periostin in tumorigenesisCellular and Molecular Life Sciences, 2009
- Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006Journal of the American Academy of Dermatology, 2009